Empowering dialysis users and caregivers
Search for dialysis centres here
Log in to explore the world's most comprehensive database of dialysis centres for free!
Professional dialysis recruitment| Analyst Rating Update on NxStage Medical, Inc. - American Trade Journal |
 |
 |
|
As many as 6 brokerage firms have rated Nxstage Medical (NASDAQ:NXTM) at 2. Research Analysts at Zacks have ranked the company at 3, suggesting the traders with a rating of hold for the short term. 1 rated the company as strong sell. The stock garnered a place in the hold list of 1 stock Analysts. 4 analysts rated the company as a strong buy. Several Brokerage firms have commented on company shares. In a research note released to the investors, Canaccord Genuity maintains its rating on NxStage Medical, Inc. (NASDAQ:NXTM).The analysts at the brokerage house have a current rating of Buy on the counter. In a recent information released to the investors, Canaccord Genuity raises the new price target from $24 per share to $27 per share. NxStage Medical, Inc. (NASDAQ:NXTM): The stock price is expected to reach $ 21 in the short term. The number of analysts agreeing with this consensus is 4. The higher estimate for the short term price target is at $24 while the lower estimate is at $15. The standard deviation of the price stands at $4.24. NxStage Medical, Inc. (NASDAQ:NXTM) : On Friday heightened volatility was witnessed in NxStage Medical, Inc. (NASDAQ:NXTM) which led to swings in the share price. The shares opened for trading at $15.4 and hit $15.89 on the upside , eventually ending the session at $15.7, with a gain of 2.15% or 0.33 points. The heightened volatility saw the trading volume jump to 622,180 shares. The 52-week high of the share price is $19.63 and the company has a market cap of $993 million. The 52-week low of the share price is at $11.5 . NxStage Medical, Inc. (NxStage) is a medical device company that develops, manufactures and markets products for the treatment of kidney failure, fluid overload and related blood treatments and procedures. The Companys primary product is the NxStage System One (System One). It also sells needles and blood tubing sets primarily to dialysis clinics for the treatment of end-stage renal disease (ESRD). It operates in two segments: System One and In-Center. It distributes its products in three markets: home, critical care and in-center. In the System One segment it derives its revenues from the sale and rental of the System One and PureFlow SL equipment, and the sale of disposable products in the home and critical care markets. In the In-Center segment, it derives its revenues from the sale of blood tubing sets and needles for hemodialysis primarily for the treatment of ESRD patients at dialysis centers and needles for apheresis, which is referred to as the in-center market. |
